Arch Biopartners Inc. (ACHFF)
OTCMKTS
· Delayed Price · Currency is USD
1.210
-0.030 (-2.42%)
May 12, 2025, 3:54 PM EDT
Arch Biopartners Revenue
Arch Biopartners had revenue of 117.87K CAD in the quarter ending December 31, 2024, a decrease of -60.47%. This brings the company's revenue in the last twelve months to 1.94M, up 5.12% year-over-year. In the fiscal year ending September 30, 2024, Arch Biopartners had annual revenue of 2.12M with 6.97% growth.
Revenue (ttm)
1.94M CAD
Revenue Growth
+5.12%
P/S Ratio
59.10
Revenue / Employee
n/a
Employees
n/a
Market Cap
79.75M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 2.12M | 138.21K | 6.97% |
Sep 30, 2023 | 1.98M | 1.02M | 105.63% |
Sep 30, 2022 | 964.68K | -2.92M | -75.18% |
Sep 30, 2021 | 3.89M | 3.82M | 5,625.22% |
Sep 30, 2020 | 67.89K | -25.99K | -27.69% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Arch Biopartners News
- 21 days ago - Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) - GlobeNewsWire
- 2 months ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire
- 3 months ago - Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI) - GlobeNewsWire
- 3 months ago - Shares for Interest Debt Settlement - GlobeNewsWire
- 4 months ago - Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) - GlobeNewsWire
- 6 months ago - Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury - GlobeNewsWire
- 7 months ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire
- 7 months ago - Closes Units for Debt Settlement - GlobeNewsWire